Related Experiment Video
Updated: Jul 6, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
PTPN22 gene polymorphism in Takayasu's arteritis.
1Marmara University Medical Faculty, Division of Rheumatology, Istanbul, Turkey.
Rheumatology (Oxford, England)
|April 1, 2008
Summary
Genetic analysis of the PTPN22 gene polymorphism did not reveal a significant association with Takayasu
Area of Science:
- Immunogenetics
- Rheumatology
- Vascular Inflammation
Background:
- Takayasu's arteritis (TA) is a rare, chronic inflammatory disease affecting the aorta and its branches.
- The etiology of TA remains largely unknown, with genetic factors suspected to play a role.
- The PTPN22 gene encodes a lymphoid-specific protein tyrosine phosphatase involved in immune regulation.
Purpose of the Study:
- To investigate the potential association between a functional single nucleotide polymorphism (SNP) in the PTPN22 gene and susceptibility to Takayasu's arteritis.
- To determine if PTPN22 gene variants influence the clinical presentation or prognosis of TA.
Main Methods:
- Genotyping of 181 TA patients and 177 healthy controls using the PCR-RFLP method for the PTPN22 rs2476601 (A/G) SNP.
- Amplification of the polymorphic region followed by digestion with the Xcm I enzyme.
Main Results:
- The frequency of the heterozygous genotype (AG) was 5.1% in controls and 3.8% in TA patients (P = 0.61).
- No statistically significant association was found between PTPN22 polymorphism and TA.
- No correlation was observed between the PTPN22 genotype and angiographic type, vascular involvement, or prognosis of TA.
Conclusions:
- The PTPN22 gene polymorphism rs2476601 (A/G) is not associated with Takayasu's arteritis in the studied Turkish population.
- These findings suggest that PTPN22 may not be a major genetic susceptibility factor for TA in this cohort.
- Further research with larger cohorts and different populations may be warranted to fully elucidate the role of PTPN22 in TA pathogenesis.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...